Kasvu Raises €30 Million for TrkB Program

Company Kasvu Therapeutics Event Type Series A Financing Modality Small Molecule (TrkB Positive Allosteric Modulator) Asset KTX-0141 Target TrkB Disease Area Major Depressive Disorder Summary Finland-based Kasvu Therapeutics raised a €30 million Series A led by Hadean Ventures, with Tesi, Innovestor and other Finnish science…